Wall Street analysts predict that Vir Biotechnology, Inc. (NASDAQ:VIR) will report $2.65 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Vir Biotechnology’s earnings, with the highest sales estimate coming in at $2.80 million and the lowest estimate coming in at $2.50 million. Vir Biotechnology reported sales of $980,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 170.4%. The business is expected to report its next quarterly earnings report on Thursday, March 25th.
According to Zacks, analysts expect that Vir Biotechnology will report full-year sales of $78.18 million for the current fiscal year, with estimates ranging from $77.13 million to $80.00 million. For the next year, analysts forecast that the company will report sales of $92.20 million, with estimates ranging from $5.00 million to $179.40 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Vir Biotechnology.
Separately, BidaskClub downgraded Vir Biotechnology from a “hold” rating to a “sell” rating in a research report on Tuesday, November 3rd.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis.
Further Reading: Insider Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.